You are here: Industry Insights > Insulin

News List

Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake expresspharma
March 17, 2021
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart).
ViaCyte, Gore to Develop Technologies that Enhance Delivery of Therapies for Diabetes americanpharmaceuticalreview
March 05, 2021
ViaCyte and W. L. Gore & Associates announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte's portfolio of ...
Biocon Biologics partners with IDF to improve access to insulins expresspharma
February 18, 2021
Biocon Biologics, a subsidiary of Biocon, has announced a partnership with the International Diabetes Federation (IDF) to promote and support IDF’s Core Mission initiative and activities.
Biocon Biologics and Viatris get EC Approval for Kixelle, biosimilar insulin Aspart expresspharma
February 18, 2021
Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above, has been approved as a 100 units/ml solution for injection in vial and pre-filled pen presentations.
ViaCyte Announces Initiation of Encapsulated Cell Therapy Study for Type 1 Diabetes americanpharmaceuticalreview
February 08, 2021
ViaCyte announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells.
New process for producing synthetic insulin developed europeanpharmaceuticalreview
January 07, 2021
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
First Patient Dosed in Trial of Ultra-Concentrated Rapid Acting Insulin Candidate for Diabetes americanpharmaceuticalreview
December 17, 2020
Arecor Limited has announced dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.
Biocon Biologics, Mylan get CHMP recommendation for approval of biosimilar insulin Aspart expresspharma
December 14, 2020
Biocon Biologics (a subsidiary of Biocon), and Mylan (a subsidiary of Viatris) have received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending approval of the market authorisation ..
T2D market will grow from a total of $48.1bn sales in 2019 to $91.9 bn in 2029 expresspharma
November 18, 2020
T2D market growth factors are increasing diagnosed prevalence of disease and emergence of novel pipeline agents.
Drug used to treat opioid addiction can reverse some adverse events caused by type 2 diabetes: Study expresspharma
November 04, 2020
IIT Mandi researchers find that low-dose naltrexone (LDN) can activate SIRT1, a critical protein molecule, thereby reducing inflammation and increasing insulin sensitivity of cells.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page